---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-224801"
form_type: "8-K"
ticker: "URGN"
cik: "0001668243"
company_name: "UroGen Pharma Ltd."
filed_at: "2024-09-24T23:59:59+00:00"
generated_at: "2026-05-31T02:05:19.815635+00:00"
event_type: "debt"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# UroGen Pharma draws $25M Tranche C loan under credit facility

## Summary
- Received $25M third tranche loan on Sept 23, 2024; proceeds for general corporate and working capital needs.
- Interest rate: 3-month SOFR + 7.25% + 0.26161% p.a., floor 2.50%, payable quarterly.
- Matures Mar 16, 2027, extended to Mar 16, 2028 if FDA approves UGN-102 by June 30, 2025.
- Repayment in four equal quarterly installments starting June 30, 2026 (or June 30, 2027 if FDA condition met).
- Loan is secured by substantially all of the credit parties' tangible and intangible assets.

## SEC filing metadata
- accession: 0001193125-24-224801
- form_type: 8-K
- ticker: URGN
- cik: 0001668243
- company_name: UroGen Pharma Ltd.
- filed_at: 2024-09-24T23:59:59+00:00
- event_type: debt
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.03
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1668243/000119312524224801/0001193125-24-224801-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1668243/000119312524224801/d849854d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-224801
- JSON: https://secwatch.observer/filing/0001193125-24-224801.json
- Plain text: https://secwatch.observer/filing/0001193125-24-224801.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.